Viraleze (astodrimer intranasal) / Starpharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  Viraleze (astodrimer intranasal) / Starpharma
    Viraleze (Twitter) -  Nov 19, 2022   
  • ||||||||||  Viraleze (astodrimer intranasal) / Starpharma
    Clinical, Journal:  Astodrimer sodium antiviral nasal spray for reducing respiratory infections is safe and well tolerated in a randomized controlled trial. (Pubmed Central) -  Jun 22, 2022   
    No systemic absorption of astodrimer sodium via the nasal mucosa was detected. Astodrimer sodium nasal spray was well tolerated and is a promising innovation warranting further investigation for nasal administration to potentially reduce infection and spread of community acquired respiratory virus infections.Trial Registration: ACTRN12620001371987, first registered 22-12-2020 (Australia New Zealand Clinical Trials Registry, https://anzctr.org.au/ ).